eligibility_summary
Adults ≥18, ECOG 0–1, histologically proven AdCC (head/neck or trachea) with recurrent/metastatic, progressive, measurable disease, adequate hematologic/renal/hepatic function, contraception/consent/insurance required. Exclude prior checkpoint inhibitors, recent chemo/RT/surgery, unresolved >G1 toxicity, untreated brain mets, recent other cancers, drug hypersensitivity, corneal/Sjögren, HIV/HBV/HCV/COVID, recent live vaccines, significant autoimmune/pulmonary/infectious/cardiac disease, QTcF>470 ms, transplants, pregnancy, major CNS/psychiatric issues.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase Ib (terminated for toxicity) in recurrent/metastatic head & neck adenoid cystic carcinoma tested: 1) OBT076, an antibody–drug conjugate (fully human IgG1) against CD205/Ly75, delivering a cytotoxic payload to CD205-high tumor cells for direct killing and potential immune activation, 2) OBT076 followed by balstilimab, a human monoclonal antibody immune checkpoint inhibitor that blocks PD‑1 to restore exhausted T-cell function. Targets/pathways: CD205/Ly75 on AdCC cells (and antigen-presenting cells), PD‑1/PD‑L1/PD‑L2 inhibitory axis on T cells (PD‑L2 often high in AdCC), tumor-infiltrating effector T cells (CD8+, CD4+, PD‑1+).